Century Therapeutics, Inc. Financing Cash Flow
Century Therapeutics, Inc. (IPSC) reported Financing Cash Flow of $126.93 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-12
- Century Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $311.00K.
- Century Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $126.62M, a 105419.17% increase year-over-year.
- Century Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $53.00K.
- Century Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Century Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $173.00K, a 99.77% decline from fiscal 2024.
- Century Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $74.56M.
- Century Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2023 was -$9.72M, a 135.81% decline from fiscal 2022.
- Century Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $27.16M, a 93.50% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 6 month as first filed | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $311.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $126.93M 10-Q · filed 2026-08-12 | $126.99M derived: sum of 3 quarters · filed 2026-08-12 | $126.99M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2026-03-31 | $126.62M 10-Q · filed 2026-05-13 | $126.68M derived: sum of 2 quarters · filed 2026-05-13 | $126.68M derived: sum of 3 quarters · filed 2026-05-13 | $126.68M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-12-31 | $53.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $53.00K derived: sum of 2 quarters · filed 2026-03-12 | $53.00K derived: sum of 3 quarters · filed 2026-08-12 | $173.00K 10-K · filed 2026-03-12 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $0.00 derived: sum of 2 quarters · filed 2026-08-12 | $120.00K 10-Q · filed 2025-11-13 | -$482.00K derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $120.00K 10-Q · filed 2026-08-12 | -$482.00K derived: sum of 3 quarters · filed 2026-08-12 | -$209.00K derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-03-31 | $120.00K 10-Q · filed 2026-05-13 | -$482.00K derived: sum of 2 quarters · filed 2026-05-13 | -$209.00K derived: sum of 3 quarters · filed 2026-05-13 | $56.49M derived: sum of 4 quarters · filed 2026-05-13 | |
| 2024-12-31 | -$602.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$329.00K derived: sum of 2 quarters · filed 2026-03-12 | $56.37M derived: sum of 3 quarters · filed 2026-03-12 | $74.56M 10-K · filed 2026-03-12 | |
| 2024-09-30 | $273.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $56.97M derived: sum of 2 quarters · filed 2025-11-13 | $75.17M 10-Q · filed 2025-11-13 | $74.81M derived: sum of 4 quarters · filed 2025-11-13 | |
| 2024-06-30 | $56.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $74.89M 10-Q · filed 2025-08-14 | $74.54M derived: sum of 3 quarters · filed 2025-08-14 | $74.84M derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-03-31 | $18.20M 10-Q · filed 2025-05-15 | $17.84M derived: sum of 2 quarters · filed 2025-05-15 | $18.14M derived: sum of 3 quarters · filed 2025-05-15 | $8.02M derived: sum of 4 quarters · filed 2025-05-15 | |
| 2023-12-31 | -$356.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | -$56.00K derived: sum of 2 quarters · filed 2025-03-19 | -$10.17M derived: sum of 3 quarters · filed 2025-03-19 | -$9.72M 10-K · filed 2025-03-19 | |
| 2023-09-30 | $300.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | -$9.82M derived: sum of 2 quarters · filed 2024-11-05 | -$9.37M 10-Q · filed 2024-11-05 | -$9.27M derived: sum of 4 quarters · filed 2024-11-05 | |
| 2023-06-30 | -$10.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$9.67M 10-Q · filed 2024-08-08 | -$9.57M derived: sum of 3 quarters · filed 2024-08-08 | -$9.44M derived: sum of 4 quarters · filed 2024-08-08 | |
| 2023-03-31 | $448.00K 10-Q · filed 2024-05-09 | $543.00K derived: sum of 2 quarters · filed 2024-05-09 | $680.00K derived: sum of 3 quarters · filed 2024-05-09 | $728.00K derived: sum of 4 quarters · filed 2024-05-09 | |
| 2022-12-31 | $95.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $232.00K derived: sum of 2 quarters · filed 2024-03-14 | $280.00K derived: sum of 3 quarters · filed 2024-03-14 | $27.16M 10-K · filed 2024-03-14 | |
| 2022-09-30 | $137.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $185.00K derived: sum of 2 quarters · filed 2023-11-09 | $27.06M 10-Q · filed 2023-11-09 | $27.17M derived: sum of 4 quarters · filed 2023-11-09 | |
| 2022-06-30 | $48.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $26.93M 10-Q · filed 2023-08-09 | $26.93M 10-Q · filed 2022-08-11 | $27.03M derived: sum of 3 quarters · filed 2023-08-09 | $26.57M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $26.88M 10-Q · filed 2023-05-11 | $26.98M derived: sum of 2 quarters · filed 2023-05-11 | $26.52M derived: sum of 3 quarters · filed 2023-05-11 | $251.17M derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | $106.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | -$360.00K derived: sum of 2 quarters · filed 2023-03-16 | $224.29M derived: sum of 3 quarters · filed 2023-03-16 | $417.77M 10-K · filed 2023-03-16 | |
| 2021-09-30 | -$466.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $224.18M derived: sum of 2 quarters · filed 2022-11-10 | $417.67M 10-Q · filed 2022-11-10 | $455.77M derived: sum of 4 quarters · filed 2022-11-10 | |
| 2021-06-30 | $224.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $418.13M 10-Q · filed 2022-08-11 | $456.23M derived: sum of 3 quarters · filed 2022-08-11 | $465.83M derived: sum of 4 quarters · filed 2022-08-11 | |
| 2021-03-31 | $193.49M 10-Q · filed 2022-05-16 | $231.59M derived: sum of 2 quarters · filed 2022-05-16 | $241.19M derived: sum of 3 quarters · filed 2022-05-16 | ||
| 2020-12-31 | $38.10M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $47.70M derived: sum of 2 quarters · filed 2022-03-17 | $47.69M 10-K · filed 2022-03-17 | ||
| 2020-09-30 | $9.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $9.59M 10-Q · filed 2021-11-10 | |||
| 2020-06-30 | -$11.00K 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |